* If you want to update the article please login/register
We will also investigate rare genetic variants and identify novel disease causes common cardiovascular disease. Individuals tested under this protocol may be the start of tailored disease-related protocols involving rigorous natural history research, disease detection, and prospective experimental therapeutic studies. This protocol can be used to recruit patients from other NIH services such as the NIH Undiagnosed Diseases Program, the Center for Human Immunology Trans-Institute Center, or other NIH protocols where cardiovascular characteristics are present.
Source link: https://clinicaltrials.gov/ct2/show/NCT01143454
The fact that multiple organs in several fibroproliferative diseases may involve multiple organs may indicate the development of common causative and pathophysiologic pathways, including epithelial cells and fibroblast cells, as well as fibroblast cells. The prevalence of left ventricular diastolic dysfunction is directly related to the high incidence of left ventricular diastolic dysfunction in patients with ischemic heart disease. However, the relationship between IPF and ischemic heart disease, as well as the prevalence of cardiac and vascular fibrosis in patients with IPF are yet to be established. Patients with idiopathic pulmonary fibrosis in patients with idiopathic pulmonary fibrosis were found in patients with invasive methods and blood biomarkers. The evaluation of the relationship between the presence and degree of pulmonary-cardiac-vascular fibrosis and the presence of biomarkers is also included in the study of the relationship between the presence / degree of vascular and /or cardiac fibrosis at baseline and disease progression at 1 year after the diagnosis of IPF. The study's primary aim is also to investigate the correlation between pulmonary fibrosis severity and serum proteomic and metabolomic biomarkers measured at baseline only in IPF patients. Participation in the research, as per normal clinical procedure, involves two visits to the IPF clinic where the patient is followed up.
Source link: https://clinicaltrials.gov/ct2/show/NCT04177251
Liver transplantation has been shown to virtually normalize plasma lipoprotein concentrations in homozygous FH, while the cloning of a functional LDL receptor gene has boosted hopes for definitive treatment of this disease. The Sequential cardiovascular research of these patients will not only describe the progression of atherosclerosis heart disease in this condition, but it will also enable the identification of people who will be able to benefit from liver transplantation and/or genetic engineering.
Source link: https://clinicaltrials.gov/ct2/show/NCT00001204
Objectives: To determine the success of novel pulse sequences for cardiovascular MRI in patients and healthy volunteers. Primary Endpoint : Achieving clinical results of pulse sequences as the number of subjects with custom and novel pulse sequences that have contributed to diagnostic quality photographs.
Source link: https://clinicaltrials.gov/ct2/show/NCT04927429
Aim 1: To determine the neurobiology of exercise and cardiovascular factors: Body to Brain hypothesis: Exercise-induced improvements in peripheral markers of cardiovascular health will precede and partly explain some of the exercise-induced changes in functional and structural characteristics of areas defining visceral control circuits. Aim 2: To determine the neurobiology of exercise-reported cardiovascular function, self-reported correlates of cardiovascular function: Exercise will lead to shifts in visceral control areas involved in functional magnetic resonance imaging experiments, and this may help to explain exercise-induced declines in cardiovascular responsiveness to daily life's challenges. Exercise will lead to changes in visceral control areas under control of an advanced magnetic resonance imaging emotion processing and control system, and this will partially account for exercise-induced improvements in influence measured in daily life by EMA and traditional self-report devices.
Source link: https://clinicaltrials.gov/ct2/show/NCT03841669
ASCEND PLUS aims to investigate the effects of the GLP1 receptor agonist, oral semaglutide, on major adverse cardiovascular events in people with type 2 diabetes who have not previously experienced a heart attack or stroke. During the scheduled treatment period and the subsequent 20-year long-term follow-up, the scheduled treatment period will be gathered by regular linkage to UK National Health Service health data related to patients with type 2 diabetes mellitus. Participants will be required to take 4-weeks of active 3mg oral semaglutide daily for four weeks before randomization, followed by four to eight weeks of active 7mg oral semaglutide daily. During the scheduled treatment period, participants who are randomised will be given either 14 mg oral semaglutide or matching placebo daily.
Source link: https://clinicaltrials.gov/ct2/show/NCT05441267
Resveratrol is found in grape leaves and skin, in peanuts, and in the plant polygonum cupsidatum's roots. A variety of biological pathways and molecular targets have been shown to vary by resveratrol's biological pathways and molecular targets with a wide variety of biological effects since then. Resveratrol may have some of the same adverse effects as reduced food intake, perhaps through its action on a protein in the body named Sirtuin, which is important because it is one of the few therapies with consistently demonstrated positive effects on the aging process. A new NIA-conducted monkey research found a decrease in the stiffness of blood vessels over several weeks, according to the animal studies. Potential uses for resveratrol as a diet aid have been identified in clinical trials in healthy human volunteers or diabetic patients with type II diabetes mellitus, and the drug appears to have no adverse effects at doses up to 5 grams per day. In 120 random overweight/obese people over the age of 50, we will perform a 12-month trial of resvidia. Participants 50 years or older can be administered two doses of study compound or placebo twice a day for 52 weeks. With different doses of the drug, experiments will be carried out to determine the amounts of resveratrol in the blood.
Source link: https://clinicaltrials.gov/ct2/show/NCT01842399
In older healthy people, a random, double blind, placebo-controlled crossover research will be conducted to see if acute intravenous angiotensin-infusion can reduce cardiovascular sympathetic tone and blood pressure, as well as improving blood vessels' functionality. This is an outpatient study that requires a screening visit, and if eligible, two research visits separated by at least one week in the Penn State Milton S. Hershey Medical Center's Clinical Research Center.
Source link: https://clinicaltrials.gov/ct2/show/NCT05301192
Obesity causes an elevated risk of cardiovascular risk factors and cardiovascular disease. Interventions based on community-based participatory research principles develop in collaboration with community partners, allowing an intervention's elements to be tailored to the community's specific needs. Based on American Heart Association-defined goals, cardiovascular health indicators can be classified as desirable, intermediate, or poor, based on knowledge of risk factors and lifestyle habits. We suspect that the proportion of the church-based population that meets established guidelines for each of the cardiovascular health risk factors will be lower than that of the population that meets intermediate and poor criteria for cardiovascular health risk factors. The findings of this community-based cardiovascular health and needs assessment will inform the design and implementation of a new community-based behavioral weight loss intervention.
Source link: https://clinicaltrials.gov/ct2/show/NCT01927783
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions